

Kevin J Anstrom

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/694711/kevin-j-anstrom-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67

papers

2,817

citations

27

h-index

52

g-index

69

ext. papers

3,779

ext. citations

10.5

avg, IF

4.67

L-index

#	Paper	IF	Citations
67	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1841-1851	27.4	12
66	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1313-1321	12.3	15
65	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. <i>JAMA Cardiology</i> , 2021 , 6, 706-712	16.2	12
64	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 14-23	10.2	6
63	Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1071-1072	27.4	
62	Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107616	3.2	0
61	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020 , 382, 1883-1893	59.2	333
60	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. <i>Respiratory Research</i> , 2020 , 21, 68	7.3	15
59	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020 , 5, 757-764	16.2	26
58	Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study. <i>JMIR Medical Informatics</i> , 2020 , 8, e15182	3.6	24
57	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1512-1521	27.4	71
56	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2302-2309.e6	1.5	21
55	Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea. <i>Heart Rhythm</i> , 2019 , 16, 91-97	6.7	13
54	NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019 , 7, 158-168	7.9	26
53	Predictive ability of perioperative atrial fibrillation risk indices in cardiac surgery patients: a retrospective cohort study. <i>Canadian Journal of Anaesthesia</i> , 2018 , 65, 786-796	3	8
52	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018 , 204, 202-204	4.9	9
51	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1764-1773	27.4	128

50	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2304-2313	15.1	11
49	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. <i>Circulation: Heart Failure</i> , 2017 , 10, e003878	7.6	29
48	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. <i>JAMA Cardiology</i> , 2017 , 2, 750-757	16.2	39
47	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	16.2	13
46	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017 , 376, 2032-2042	59.2	156
45	Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 331-341	15.1	261
44	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017 , 40, 38-45	3.3	11
43	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	36
42	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	4
41	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CYB) trial. <i>Annals of Thoracic Surgery</i> , 2016 , 102, 69-74	4.9	20
40	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2016 , 1, 655-65	16.2	11
39	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment With Adenosine Diphosphate Receptor Inhibitors). <i>Circulation</i> , 2016 , 133, 39-47	6	15
38	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. <i>Circulation</i> , 2016 , 133, 39-47	16.7	46
37	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016 , 117, 404-11	3	38
36	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , 2016 , 5, e12	2.1	3
35	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. <i>American Heart Journal</i> , 2016 , 177, 33-41	4.9	11
34	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	29
33	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease: Results From the PROMISE Randomized Trial. <i>Circulation</i> , 2016 , 133, 1995-2007	16.7	26

32	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5,	6	8
31	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9,	6.4	15
30	Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 726-35	7.9	27
29	Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare-linked National Cardiovascular Data Registry() CathPCI Registry() (2005-2009). <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 43-9	2.7	12
28	Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 145-51	6.4	10
27	Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001710	6	10
26	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 388-96	35.1	57
25	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. <i>Circulation</i> , 2015, 131, 1763-71	16.7	173
24	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). <i>Circulation: Heart Failure</i> , 2015, 8, 741-8	7.6	147
23	Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001403	6	37
22	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015, 4, e002061	6	9
21	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 188-200	4.3	59
20	Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. <i>Journal of the American College of Cardiology</i> , 2015, 65, 465-76	15.1	21
19	Primary prevention implantable cardioverter-defibrillators and survival in older women. <i>JACC: Heart Failure</i> , 2015, 3, 159-67	7.9	26
18	Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. <i>Circulation: Heart Failure</i> , 2015, 8, 221-8	7.6	29
17	Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-9	6.4	31
16	Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. <i>American Journal of Cardiology</i> , 2014, 114, 716-22	3	7
15	Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 457-65	7.9	84

14	Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. <i>Chest</i> , 2014 , 146, 1256-1262	5.3	24
13	Examination of the treatment selection process in a multicenter observational study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 764-9	5.8	
12	Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2209-15	27.4	24
11	Racial/Ethnic differences in process of care and outcomes among patients hospitalized with intracerebral hemorrhage. <i>Stroke</i> , 2014 , 45, 3243-50	6.7	28
10	GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. <i>Circulation: Heart Failure</i> , 2014 , 7, 673-9	7.6	33
9	PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial. <i>American Heart Journal</i> , 2014 , 167, 796-803.e1	4.9	76
8	Percutaneous coronary intervention and drug-eluting stent use among patients 85 years of age in the United States. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 105-12	15.1	34
7	Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1044-8	10.2	165
6	A generalized estimator of the attributable benefit of an optimal treatment regime. <i>Biometrics</i> , 2010 , 66, 512-22	1.8	28
5	Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1629-41	15.1	117
4	Long-term clinical outcomes following coronary stenting. <i>Archives of Internal Medicine</i> , 2008 , 168, 1647-55		11
3	Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004 , 101, 2584-92	6.4	30
2	Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study (Preprint)		1
1	Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ)		3